trending Market Intelligence /marketintelligence/en/news-insights/trending/kyEBGLZvtqL3k2TT-nk73A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Jubilant's India facility gets FDA warning letter for drug quality violations

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Jubilant's India facility gets FDA warning letter for drug quality violations

The U.S. Food and Drug Administration issued a warning letter to Jubilant Life Sciences Ltd.'s manufacturing plant in India for not investigating drug quality and customer complaints.

In a March 6 letter, the U.S. regulator said the Jubilant's facility in Roorkee, in the state of Uttaranchal, did not test all batches of a product at its quality-control lab after one batch failed the quality test, something the company's management had been warned about previously.

The FDA also said the company did not thoroughly investigate customer complaints regarding damage to the coating of certain delayed-release tablets, which could affect dissolution.

The agency said it may withhold any pending approval applications or supplements from the company's facility until it corrects all violations.

In December 2018, the FDA recommended regulatory action after an inspection of the facility and said it may withhold any pending approval applications or supplements from Jubilant's Roorkee facility of solid dosage formulations.

India-based Jubilant manufactures and supplies active pharmaceutical ingredients and nutritional products, among others.